Shares of NICE Ltd. (NASDAQ:NICE – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen analysts that are currently covering the company, MarketBeat reports. Fifteen research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $269.64.
A number of equities analysts have recently issued reports on the company. Rosenblatt Securities reissued a “buy” rating and issued a $225.00 target price on shares of NICE in a report on Tuesday, August 13th. Northland Securities dropped their price objective on NICE from $305.00 to $275.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Piper Sandler reduced their target price on shares of NICE from $238.00 to $213.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 10th. JMP Securities reiterated a “market outperform” rating and set a $300.00 target price on shares of NICE in a research report on Friday, August 16th. Finally, Wedbush restated an “outperform” rating and issued a $250.00 price target on shares of NICE in a research report on Friday, August 16th.
Get Our Latest Stock Analysis on NICE
NICE Trading Down 1.4 %
NICE (NASDAQ:NICE – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The technology company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.58 by $0.06. The firm had revenue of $664.40 million for the quarter, compared to the consensus estimate of $664.10 million. NICE had a net margin of 15.55% and a return on equity of 14.68%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.63 earnings per share. As a group, research analysts predict that NICE will post 8.5 earnings per share for the current year.
Institutional Trading of NICE
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Hawaiian Bank acquired a new stake in shares of NICE during the 2nd quarter worth approximately $516,000. Diversified Trust Co raised its position in shares of NICE by 237.9% during the 2nd quarter. Diversified Trust Co now owns 6,478 shares of the technology company’s stock valued at $1,114,000 after acquiring an additional 4,561 shares during the last quarter. Capital World Investors acquired a new position in shares of NICE in the 1st quarter valued at $9,699,000. Osborne Partners Capital Management LLC boosted its position in shares of NICE by 6.4% in the 3rd quarter. Osborne Partners Capital Management LLC now owns 67,821 shares of the technology company’s stock worth $11,778,000 after purchasing an additional 4,080 shares during the last quarter. Finally, Bayesian Capital Management LP grew its stake in shares of NICE by 160.6% during the first quarter. Bayesian Capital Management LP now owns 7,465 shares of the technology company’s stock worth $1,946,000 after purchasing an additional 4,600 shares during the period. 63.34% of the stock is currently owned by institutional investors and hedge funds.
NICE Company Profile
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for the customer engagement market; and smart self service enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing.
See Also
- Five stocks we like better than NICE
- How to Calculate Return on Investment (ROI)
- Intel: Is Now the Time to Be Brave?Â
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Which Wall Street Analysts are the Most Accurate?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for NICE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NICE and related companies with MarketBeat.com's FREE daily email newsletter.